New Biomaterials: What Problems Need Solving? What Lessons have been Learned?


Thursday, June 16 | 11:15 am - 12:00 pm


Tech Center


All Levels

Participant Type:

Product Development, Manufacturing, Quality/Regulatory

New materials will play a critical role in the advancement of orthopedics, as companies seek to positively impact the outcomes of popular procedures and even develop solutions to help the body regenerate. Bringing new materials to market is a lengthy and challenging process, though. It involves years of research, numerous regulatory hurdles and significant surgeon education. This session brings together companies commercializing next-generation biomaterials. Each will share the specifics about their materials and implants, and lessons they’ve learned throughout the process.

The companies include: BioPoly and their “Bio” = hyaluronic acid (HA) and “Poly” = Ultrahigh molecular weight polyethylene (UHMWPE) implant designed to replace damaged cartilage. Biorez and their BioBrace implant, a bioinductive scaffold that is intended to reinforce soft tissue where weakness exists, and promote soft tissue healing. Dimension Inx. and their Hyperelastic Bone, a calcium phosphate-based 3D paint used to create surgically friendly, flexible implants that generate new bone.

Learning Objectives

  • Knowledge of next-generation materials in research and on the market

  • Lessons learned in getting to market, including regulatory clearance, clinical studies and commercialization strategy

  • Future applications for new materials


Robert A. Poggie, Ph.D.




Kevin Rocco

President, CEO and Founder,


Herb Schwartz, Ph.D.

President, CEO and Founder,


Ramille Shah, Ph.D.

Co-Founder and Chief Scientific Officer,

Dimension Inx